|
1
|
Huang J, Ye X, Guan J, Chen B, Li Q, Zheng
X, Liu L, Wang S, Ding Y, Ding Y and Chen L: Tiam1 is associated
with hepatocellular carcinoma metastasis. Int J Cancer. 132:90–100.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Balogh J, Victor D III, Asham EH,
Burroughs SG, Boktour M, Saharia A, Li X, Ghobrial RM and Monsour
HP Jr: Hepatocellular carcinoma: A review. J Hepatocell Carcinoma.
3:41–53. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ringelhan M, McKeating JA and Protzer U:
Viral hepatitis and liver cancer. Philos Trans R Soc Lond B Biol
Sci. 372:20160274. 2017.PubMed/NCBI
|
|
4
|
Fujiwara N, Friedman SL, Goossens N and
Hoshida Y: Risk factors and prevention of hepatocellular carcinoma
in the era of precision medicine. J Hepatol. 68:526–549. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Levrero M and Zucman-Rossi J: Mechanisms
of HBV-induced hepatocellular carcinoma. J Hepatol. 64:S84–S101.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wang S, Chen N, Chen Y, Sun L, Li L and
Liu H: Elevated GPC3 level promotes cell proliferation in liver
cancer. Oncol Lett. 16:970–976. 2018.PubMed/NCBI
|
|
7
|
Tian Y and Ou JH: Genetic and epigenetic
alterations in hepatitis B virus-associated hepatocellular
carcinoma. Virol Sin. 30:85–91. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Trepo C, Chan HL and Lok A: Hepatitis B
virus infection. Lancet. 384:2053–2063. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Sung WK, Zheng H, Li S, Chen R, Liu X, Li
Y, Lee NP, Lee WH, Ariyaratne PN, Tennakoon C, et al: Genome-wide
survey of recurrent HBV integration in hepatocellular carcinoma.
Nat Genet. 44:765–769. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
Buendia MA and Neuveut C: Hepatocellular
carcinoma. Cold Spring Harb Perspect Med. 5:a0214442015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Murakami Y, Saigo K, Takashima H, Minami
M, Okanoue T, Bréchot C and Paterlini-Bréchot P: Large scaled
analysis of hepatitis B virus (HBV) DNA integration in HBV related
hepatocellular carcinomas. Gut. 54:1162–1168. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lau CC, Sun T, Ching AK, He M, Li JW, Wong
AM, Co NN, Chan AW, Li PS, Lung RW, et al: Viral-human chimeric
transcript predisposes risk to liver cancer development and
progression. Cancer Cell. 25:335–349. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Tropberger P, Mercier A, Robinson M, Zhong
W, Ganem DE and Holdorf M: Mapping of histone modifications in
episomal HBV cccDNA uncovers an unusual chromatin organization
amenable to epigenetic manipulation. Proc Natl Acad Sci USA.
112:E5715–E5724. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ringelhan M, O'Connor T, Protzer U and
Heikenwalder M: The direct and indirect roles of HBV in liver
cancer: Prospective markers for HCC screening and potential
therapeutic targets. J Pathol. 235:355–367. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Menolfi D, Delamarre A, Lengronne A,
Pasero P and Branzei D: Essential roles of the Smc5/6 complex in
replication through natural pausing sites and endogenous DNA damage
tolerance. Mol Cell. 60:835–846. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wang HC, Huang W, Lai MD and Su IJ:
Hepatitis B virus pre-S mutants, endoplasmic reticulum stress and
hepatocarcinogenesis. Cancer Sci. 97:683–688. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Weber A, Boege Y, Reisinger F and
Heikenwälder M: Chronic liver inflammation and hepatocellular
carcinoma: Persistence matters. Swiss Med Wkly.
141:w131972011.PubMed/NCBI
|
|
18
|
Chao CC: Inhibition of apoptosis by
oncogenic hepatitis B virus X protein: Implications for the
treatment of hepatocellular carcinoma. World J Hepatol.
8:1061–1066. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Chang CS, Huang SM, Lin HH, Wu CC and Wang
CJ: Different expression of apoptotic proteins between HBV-
infected and non-HBV-infected hepatocellular carcinoma.
Hepatogastroenterology. 54:2061–2068. 2007.PubMed/NCBI
|
|
20
|
Fattovich G, Stroffolini T, Zagni I and
Donato F: Hepatocellular carcinoma in cirrhosis: Incidence and risk
factors. Gastroenterology. 127:S35–S50. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Sunami Y, Ringelhan M, Kokai E, Lu M,
O'Connor T, Lorentzen A, Weber A, Rodewald AK, Müllhaupt B,
Terracciano L, et al: Canonical NF-κB signaling in hepatocytes acts
as a tumor-suppressor in hepatitis B virus surface antigen-driven
hepatocellular carcinoma by controlling the unfolded protein
response. Hepatology. 63:1592–1607. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wang Q, Wang X and Evers BM: Induction of
cIAP-2 in human colon cancer cells through PKC delta/NF-kappa B. J
Biol Chem. 278:51091–51099. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Gill C, Dowling C, O'Neill AJ and Watson
RW: Effects of cIAP-1, cIAP-2 and XIAP triple knockdown on prostate
cancer cell susceptibility to apoptosis, cell survival and
proliferation. Mol Cancer. 8:392009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wu HH, Wu JY, Cheng YW, Chen CY, Lee MC,
Goan YG and Lee H: cIAP2 upregulated by E6 oncoprotein via
epidermal growth factor receptor/phosphatidylinositol 3-kinase/AKT
pathway confers resistance to cisplatin in human papillomavirus
16/18-infected lung cancer. Clin Cancer Res. 16:5200–5210. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Miura K, Karasawa H and Sasaki I: cIAP2 as
a therapeutic target in colorectal cancer and other malignancies.
Expert Opin Ther Targets. 13:1333–1345. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Huang W, Hu K, Luo S, Zhang M, Li C, Jin
W, Liu Y, Griffin GE, Shattock RJ and Hu Q: Herpes simplex virus
type 2 infection of human epithelial cells induces CXCL9 expression
and CD4+ T cell migration via activation of
p38-CCAAT/enhancer-binding protein-β pathway. J Immunol.
188:6247–6257. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yoneda M, Hyun J, Jakubski S, Saito S,
Nakajima A, Schiff ER and Thomas E: Hepatitis B virus and DNA
stimulation trigger a rapid innate immune response through NF-κB. J
Immunol. 197:630–643. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Mrani S, Chemin I, Menouar K, Guillaud O,
Pradat P, Borghi G, Trabaud MA, Chevallier P, Chevallier M, Zoulim
F and Trépo C: Occult HBV infection may represent a major risk
factor of non-response to antiviral therapy of chronic hepatitis C.
J Med Virol. 79:1075–1081. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Hu K, He S, Xiao J, Li M, Luo S, Zhang M
and Hu Q: Interaction between herpesvirus entry mediator and HSV-2
glycoproteins mediates HIV-1 entry of HSV-2-infected epithelial
cells. J Gen Virol. 98:2351–2361. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Liu D, Zhu Y, Pang J, Weng X, Feng X and
Guo Y: Knockdown of long non-coding RNA MALAT1 inhibits growth and
motility of human hepatoma cells via modulation of miR-195. J Cell
Biochem. 119:1368–1380. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Hong SY, Yoon WH, Park JH, Kang SG, Ahn JH
and Lee TH: Involvement of two NF-kappa B binding elements in tumor
necrosis factor alpha-, CD40-, and epstein-barr virus latent
membrane protein 1-mediated induction of the cellular inhibitor of
apoptosis protein 2 gene. J Biol Chem. 275:18022–18028. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Satoh T, Okamoto I, Miyazaki M, Morinaga
R, Tsuya A, Hasegawa Y, Terashima M, Ueda S, Fukuoka M, Ariyoshi Y,
et al: Phase I study of YM155, a novel survivin suppressant, in
patients with advanced solid tumors. Clin Cancer Res. 15:3872–3880.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Shimizu T, Nishio K, Sakai K, Hayashi H,
Okamoto K, Takeda M, Iwasa T, Tanaka K, Aoyama K, Morishita M and
Nakagawa K: Phase I study of YM155, selective survivin suppressant
in combination with elrotnib in patients with EGFR-mutant advanced
non-small cell lung cancer. J Clin Oncol. 34:e205852016. View Article : Google Scholar
|
|
35
|
Papadopoulos KP, Lopez-Jimenez J, Smith
SE, Steinberg J, Keating A, Sasse C, Jie F and Thyss A: A
multicenter phase II study of sepantronium bromide (YM155) plus
rituximab in patients with relapsed aggressive B-cell Non-Hodgkin
lymphoma. Leuk Lymphoma. 57:1848–1855. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Benetatos CA, Mitsuuchi Y, Burns JM,
Neiman EM, Condon SM, Yu G, Seipel ME, Kapoor GS, Laporte MG,
Rippin SR, et al: Birinapant (TL32711), a bivalent SMAC mimetic,
targets TRAF2-associated cIAPs, abrogates TNF-induced NF-κB
activation, and is active in patient-derived xenograft models. Mol
Cancer Ther. 13:867–879. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Amaravadi RK, Schilder RJ, Martin LP,
Levin M, Graham MA, Weng DE and Adjei AA: A phase I study of the
SMAC-mimetic birinapant in adults with refractory solid tumors or
lymphoma. Mol Cancer Ther. 14:2569–2575. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Crawford N, Salvucci M, Hellwig CT,
Lincoln FA, Mooney RE, O'Connor CL, Prehn JH, Longley DB and Rehm
M: Simulating and predicting cellular and in vivo responses of
colon cancer to combined treatment with chemotherapy and IAP
antagonist Birinapant/TL32711. Cell Death Differ. 25:1952–1966.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Wang SQ and Wu JG: Biological effects of
HBV X protein on hepatocellular carcinogenesis in association with
cellular factors. Virol Sin. 23:146–151. 2008. View Article : Google Scholar
|
|
40
|
Lee WY, Bachtiar M, Choo CCS and Lee CG:
Comprehensive review of Hepatitis B Virus-associated hepatocellular
carcinoma research through text mining and big data analytics. Biol
Rev Camb Philos Soc. 94:353–367. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Li YW, Yang FC, Lu HQ and Zhang JS:
Hepatocellular carcinoma and hepatitis B surface protein. World J
Gastroenterol. 22:1943–1952. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Liu W, Lin YT, Yan XL, Ding YL, Wu YL,
Chen WN and Lin X: Hepatitis B virus core protein inhibits
Fas-mediated apoptosis of hepatoma cells via regulation of
mFas/FasL and sFas expression. FASEB J. 29:1113–1123. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Tuttle RL, Gill NS, Pugh W, Lee JP,
Koeberlein B, Furth EE, Polonsky KS, Naji A and Birnbaum MJ:
Regulation of pancreatic beta-cell growth and survival by the
serine/threonine protein kinase Akt1/PKBalpha. Nat Med.
7:1133–1137. 2001. View Article : Google Scholar : PubMed/NCBI
|
